Overview

Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.

Status:
ENROLLING_BY_INVITATION

Trial end date:
2026-08-31

Target enrollment:

Participant gender:

Summary

This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated with Ibrutinib for 3 months prior to leukapheresis.

Phase:

PHASE1

Details

Lead Sponsor:

Vitebsk Regional Clinical Cancer Centre

Collaborator:

Republican Scientific and Practical Center for children's Oncology, Hematology and Immunology

Treatments:

Lenalidomide